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Fluoxetine (FX) is a chiral fluorinated pharmaceutical indicated mainly for treatment of 
depression and is one of the most dispensed drugs in the world. Environmental 
contamination with this drug and its active metabolite norfluoxetine (Nor-FX) has been 
detected in sewage effluents and in surface waters. Microbial degradation of this 
compound is largely unknown. Moreover, the biodegradation of enantiomers in chiral 
pharmaceuticals in the environment is scarcely studied.  
The biodegradation of FX was achieved by the wild strain Labrys portucalensis F11. 
When FX was supplied as sole carbon source, strain F11 was able to biodegrade 2 µM 
of FX in 20 days with stoichiometric liberation of fluoride. When sodium acetate was 
added, strain F11 was able to biodegrade the total amount of 21 µM of FX, with 
liberation of half of the stoichiometrically expected fluoride. In both experiments, Nor-
FX was detected as intermediary metabolite during biodegradation. Experiments 
revealed higher biodegradation extent for the R-enantiomeric form of FX and the 
formation of only one enantiomer of the metabolite Nor-FX as indicated by the 
enantioselective HPLC method developed. To the best of our knowledge this is the first 
time that biodegradation of fluoxetine is reported. 
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